Advanced Cancer

Chemoimmunotherapy prolongs PFS in metastatic triple-negative breast cancer

Chemoimmunotherapy prolongs PFS in metastatic triple-negative breast cancer

By

A prospective analysis of patients with advanced cancer revealed the effect delirium has on palliative care and symptom management at baseline and after 7 days of treatment.

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

CheckMate 067 Gives Nivolumab Alone, With Ipilimumab the Nod in Advanced Melanoma

By

Survival and progression-free survival were better with nivolumab alone or with ipilimumab vs ipilimumab alone for stage III or IV melanoma with known BRAFV600 mutation, according to results of this randomized study.

Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC

Early Checkpoint Inhibition With Cytotoxic Chemotherapy Improves OS, PFS in Extensive-Stage SCLC

By

In this randomized, double-blind, placebo-controlled study, researchers sought to determine the effect of including a checkpoint inhibitor in induction therapy for patients with extensive-stage small cell lung cancer.

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

Nedaplatin vs Cisplatin for Malignancy-Induced MPE: Noninferior, Less Toxicity

By

Researchers sought to determine if nedaplatin could effectively manage malignancy-induced MPE in patients with cancer with less toxicity than cisplatin.

Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?

Current Status and Dilemma of Second-line Treatment in Advanced Pancreatic Cancer: Is There a Silver Lining?

[OncoTargets and Therapy] Although first-line therapy is effective, relapse is common; but many patients are good candidates for second-line therapy. This report reviews current published data on second-line therapies for advanced pancreatic cancer.

Using Palliative Care to Improve Lung Cancer Outcomes in Veterans at Risk of Suicide

Using Palliative Care to Improve Lung Cancer Outcomes in Veterans at Risk of Suicide

By

In a review of data from more than 20,000 veterans, researchers determined the effects of palliative care on suicide rates among veterans with advanced lung cancer.

Data on Corticosteroid-Related Adverse Events in Advanced Cancer Are Lacking, Needed

Data on Corticosteroid-Related Adverse Events in Advanced Cancer Are Lacking, Needed

By

Although corticosteroids are frequently used to manage adverse effects (AEs), data on AEs related to these agents are lacking. Therefore, these researchers sought to determine if better reporting of corticosteroid-related AEs would be of benefit.

PTSD May Increase Symptom Burden in Patients With Cancer

PTSD May Increase Symptom Burden in Patients With Cancer

Post-traumatic stress symptoms are linked to a greater symptom burden in hospitalized cancer patients.

Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life

Managing Dyspnea With Fentanyl in Patients With Cancer at End of Life

By

In this retrospective study, researchers sought to determine the effectiveness of fentanyl for dyspnea in dying patients with advanced cancer.

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

Long-term Survival Improving Over Time in Advanced Hodgkin Lymphoma

By

A review of SEER data revealed trends in incidence of advanced Hodgkin lymphoma, discrepancies among subgroups, and survival over 3 decades.

Hope, Optimism Reduce Psychological Distress in Advanced Cancer

Hope, Optimism Reduce Psychological Distress in Advanced Cancer

By

A cross-sectional analysis evaluated the impact of hope and optimism on different facets of psychological distress among patients with advanced melanoma, colorectal, lung, or gastrointestinal cancers.

Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer

Palliative Sedation a Valid Option for Refractory Symptoms in End-stage Cancer

By

A prospective study was conducted to determine the effectiveness of palliative sedation for patients with terminal illnesses who experience refractory symptoms.

Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer

Modified XELIRI Noninferior to FOLFIRI for OS in Metastatic Colorectal Cancer

By

Results of the phase 3 AXEPT study were used to determine the noninferiority of a modified XELIRI regimen vs a FOLFIRI regimen in terms of overall survival among patients with metastatic colorectal cancer (mCRC).

Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer

Various Aspects of Palliative Care Focus Associated With Different Outcomes In Cancer

By

In this evaluation of palliative care use, investigators were able to determine how the focus of palliative care - coping, treatment, or advanced care planning - influenced patients' decisions on quality of life and decisions regarding chemotherapy and hospice care at the end of life.

Exercise, Fitness Significantly Decrease After Advanced Lung Cancer Diagnosis

Exercise, Fitness Significantly Decrease After Advanced Lung Cancer Diagnosis

By

Using MVIC and 6MWT, researchers sought to determine if patients' exercise behaviors changed after a diagnosis of advanced lung cancer.

Early Integration of Palliative Care Improves Quality of Life in Advanced Cancer

Early Integration of Palliative Care Improves Quality of Life in Advanced Cancer

Results of a nonblinded study demonstrate the value of incorporating early palliative care into oncologic care for patients with advanced cancer.

High Opioid Use Linked to Shorter Cancer Survival, Increased Health Care Use

High Opioid Use Linked to Shorter Cancer Survival, Increased Health Care Use

By

Researchers sought to determine the link between opioid use among patients with advanced cancer and health care use such as urgent care, inpatient, and emergency room visits.

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

Partial Response Achieved With Atezolizumab, Cobimetinib in Pretreated CRC

By

Safety and efficacy of atezolizumab with cobimetinib for heavily pretreated metastatic CRC was demonstrated in a phase 1b study that was presented at the 2018 Gastrointestinal Cancers Symposium.

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

FDA Grants Breakthrough Therapy Designation to Lenvatinib Plus Pembrolizumab for RCC

By

Combination therapy with lenvatinib and pembrolizumab is granted Breakthrough Therapy Designation for the treatment of advanced or metastatic renal cell carcinoma (RCC).

Nurses Must Be Experienced, Feel Competent When Providing End-of-Life Care

Nurses Must Be Experienced, Feel Competent When Providing End-of-Life Care

By

An analysis of select responses to a survey conducted by researchers from the College of Nursing at South Dakota State University identified oncology nurses' comfort level in handling end-of-life care and patient education.

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

Quality of Life During Maintenance Therapy Better With Lower Dose, More Often

By

Trial investigates which of 3 maintenance regimens of nab-paclitaxel has the most ideal impact on quality of life in patients with metastatic breast cancer. Results were presented at SABCS 2017.

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

Partial Response Reported With Abemaciclib for Breast Cancer Metastases to Brain

By

Researchers seeking to determine whether breast cancer metastases to the brain would respond to abemaciclib presented the results of a phase 2 Simon 2-stage trial at SABCS 2017.

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

Challenging the Standard of Care in Advanced Melanoma: Focus on Pembrolizumab

[Cancer Management and Research] This study examines the advances that pembrolizumab has made in melanoma and upcoming research that may further improve melanoma treatment.

Outcomes Best With Discharge to Home vs PAC or Hospice in Advanced Cancer

Outcomes Best With Discharge to Home vs PAC or Hospice in Advanced Cancer

By

In a prospective study, researchers assessed survival and quality of life measures for patients with advanced cancer in relation to where they are discharged from hospital: postacute care (PAC), hospice, or home without hospice.

Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer

Palliative Care Associated With Decreased Costs For Patients With Advanced Cancer

By

Previous studies have shown that patients with advanced cancer may experience some financial relief integrating palliative care with standard oncologic care, but these results were coincidental findings and have not yet been fully explored.

WWW: Navigating Complex Conversations Regarding Patients With Advanced Disease

WWW: Navigating Complex Conversations Regarding Patients With Advanced Disease

By

WWW is not for the world-wide web, but it is an easy way to remember the 3 w's of communication with patients with advanced disease: wish, worry, wonder.

Hospitalizations in Advanced Cancer: What Makes Patients Stay or Come Back

Hospitalizations in Advanced Cancer: What Makes Patients Stay or Come Back

By

Investigators conducted a study involving more than 1000 patients with advanced cancer to assess the factors that contribute to prolonged hospital stays and increased risk for readmissions.

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

Progression-Free, Overall Survival in Liposarcoma Improved With Eribulin vs Dacarbazine

By

Comparison study shows significantly improved overall survival and progression-free survival in patients with advanced LPS treated with eribulin vs dacarbazine.

Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose

Cabazitaxel in Prostate Cancer: Reduced Dose Noninferior to Standard Dose

By

A smaller dose of cabazitaxel (C20) is noninferior to a larger dose (C25) in the post-docetaxel treatment of mCRPC.

Combination Better At Easing Agitated Delirium in Advanced Cancer Patients

Combination Better At Easing Agitated Delirium in Advanced Cancer Patients

By

Lorazepam plus haloperidol is more effective than haloperidol alone at reducing agitation, study finds.

Sign Up for Free e-newsletters



Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs